top of page

NCI-2022-05056

Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma (Phase II Study)


This is a medical study to evaluate the safety and efficacy of tislelizumab in combination with other liver-directed therapies for the treatment of hepatocellular carcinoma (HCC), a type of liver cancer.

The study is in phase II, which means it is in its early stages and researchers are trying to determine the safety and effectiveness of the treatment. The treatment being studied is tislelizumab, a drug that is designed to help the immune system attack cancer cells. Tislelizumab is being combined with other liver-directed therapies, which are treatments that target the liver. The study is for people with hepatocellular carcinoma.


For more information about the trial, click the link below:

NCI-2022-05056

Clinical Trial Site: Einstein


To see all available clinical trials click here.



Recent Posts

See All

NCI-2022-06272

A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064

NCI-2019-04202

A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC. Some patients have a tumor that is “resectable,” which means that it is able to be rem

NCI-2020-07076

A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors Antibodies are part of our body's defense system. They can specifically recognize damaging substances in the body, including tumor cell

bottom of page